Novel targets in gastric and esophageal cancer

Critical Reviews in Oncology/Hematology

Volumn 59, Issue 2, 2006, Pages 128-138

  Valverde, Claudia María ^a   Macarulla, Teresa ^a   Casado, Esther ^a   Ramos, Francisco Javier ^a   Martinelli, Erika ^a   Tabernero, Josep ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Angiogenesis inhibitors; EGFR inhibitors; Esophageal cancer; Gastric cancer; Targeted therapies

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BORTEZOMIB; CANERTINIB; CETUXIMAB; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLAVOPIRIDOL; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; LAPATINIB; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MATUZUMAB; PACLITAXEL; PANITUMUMAB; PELITINIB; PERTUZUMAB; SEMAXANIB; SUNITINIB; UNINDEXED DRUG; VANDETANIB; VATALANIB;

ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CELL CYCLE REGULATION; CLINICAL TRIAL; DATA ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; ESOPHAGUS CANCER; HUMAN; IN VITRO STUDY; MOLECULAR WEIGHT; NONHUMAN; PERFORATION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; VEIN DISEASE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; DRUG DESIGN; ESOPHAGEAL NEOPLASMS; HUMANS; MATRIX METALLOPROTEINASE 1; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 33746232378     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2006.02.001     Document Type: Review

References (77)

1. Devesa S.S., Blot W.J., and Fraumeni F.J.F. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83 (1998) 2049-2053
2. Blot W.J., and McLaughlin J.K. The changing epidemiology of esophageal cancer. Semin Oncol 26 Suppl. 15 (1999) 2-8
3. Pozzo C., Barone C., Szanto J., et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol 15 (2004) 1773-1781
4. Bouche O., Raoul J.L., Bonnetain F., et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and Leucovorin (LV5FU2), LV5FU2 plus cisplatin or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803. J Clin Oncol 22 (2004) 4319-4328
5. Roth A.D., Maibach R., Falk S., et al. Docetaxel-cisplatin-5FU (TCF) versus docetaxel-cisplatin (TC) as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). Proc Am Soc Clin Oncol 23 (2004) 317 (A4020)
6. Ajani J.A., Van Cutsem E., Moiseyenko V., et al. Docetaxel, cisplatin, 5-fluorouracil compare to cisplatin and 5-fluorouracil for chemotherapy-naïve patients with metastasic or locally recurrent, unresectable gastric carcinoma: interim results of a randomized phase III trial (V325). Proc Am Soc Clin Oncol 22 (2003) 249 (A999)
7. Tournigand C., André T., Achille E., et al. FOLFIRI Followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR Study. J Clin Oncol 22 (2004) 229-237
8. Goldberg R.M., Sargent D.J., Morton R.F., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22 (2004) 23-30
9. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
10. Rojo F., Albanell J., Sauleda S., et al. Characterization of epidermal growth factor (EGF) receptor and transforming growth factor (TGF) alpha expression in gastric cancer and its association with activation of mitogen-activated protein kinase (MAPK). Proc Am Soc Clin Oncol 20 (2001) 430a (A1717)
11. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 20 (2002) 1S-13S
12. Baselga J., Pfister D., Cooper M.R., et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18 (2000) 904-914
13. Saltz L.B., Meropol N.J., Loehrer Sr. P.J., et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22 (2004) 1201-1208
14. Saltz L., Rubin M., Hochster H., et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 20 (2001) 3a (A7, updated information presented at meeting)
15. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
16. Ciardiello F., Bianco R., Damiano V., et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 5 (1999) 909-916
17. Prewett M., Hooper A.T., Bassi R., et al. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Cancer Res 8 (2002) 994-1003
18. Tabernero J., Rojo F., Jimenez E., et al. A Phase I PK and Serial Tumor and Skin Pharmacodynamic (PD) Study of weekly (Q1w), every 2-week (Q2w) or every 3-week (Q3w) 1-hour (H) infusion EMD72000, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (Pt) with advanced tumors. Proc Am Soc Clin Oncol 22 (2003) 192 (A770)
19. Vanhoefer U., Tewes M., Rojo F., et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 22 (2004) 175-184
20. Hecht J.R., Patnaik A., Malik I., et al. ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): an updated analysis. Proc Am Soc Clin Oncol 23 (2004) 247s (A3511)
21. Tanner M., Hollmen M., Junttila T.T., et al. Amplification of Her-2 in gastric carcinoma: association with topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16 (2005) 273-278
22. Agus D., Gordon M., Taylor C., et al. Phase I clinical study of pertuzumab, a novel Her dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 23 (2005) 2534-2543
23. Doi T., Koizumi W., Siena S., et al. Efficacy, tolerability and pharmacokinetics of gefitinib (ZD1839) in pretreated patients with metastatic gastric cancer. Proc Am Soc Clin Oncol 22 (2003) 258 (A1036)
24. Rojo J., Tabernero E., Van Cutsem E., et al. Pharmacodynamic studies of tumor biopsy specimens from patients with advanced gastric carcinoma undergoing treatment with gefitinib (ZD1839). Proc Am Soc Clin Oncol 22 (2003) 191 (A764)
25. Ferry D.R., Anderson M., Beddows K., et al. Phase II trial of gefitinib (ZD1839) in advanced adenocarcinoma of the oesophagus incorporating biopsy before and after gefitinib. Proc Am Soc Clin Oncol 23 (2004) 317 (A4021)
26. Van Groeningen C., Richel D., Giaccone G., et al. Gefitinib phase II study in second-line treatment of advanced esophageal cancer. Proc Am Soc Clin Oncol 23 (2004) 318 (A4022)
27. Adelstein D.J., Rybicki L.A., Carrol M.A., Rice T.W., and Meckhail T. Phase II trial of gefitinib for recurrent or metastatic esophageal or gastroesophageal junction (GEJ) cancer. Proc Am Soc Clin Oncol 23 (2005) 321s (A4054)
28. Tew W.P., Shah M., Schwartz G., et al. Phase II trial of erlotinib for second-line treatment in advanced esophageal cancer. Proc Gastrointest Am Soc Clin Oncol Symp 85 (2005) A5
29. Dragovich T., McCoy S., Urba S.G., et al. SWOG 0127 phase II trial of erlotinib in GEJ and gastric adenocarcinomas. Proc Gastrointest Am Soc Clin Oncol Symp 107 (2005) A49
30. Ciardiello F., Caputo R., Bianco R., et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6 (2000) 2053-2063
31. Kishida O., Miiyazaki Y., Murayama Y., et al. Gefitinib ("Iressa", ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells. Cancer Chemother Pharmacol 55 (2005) 393-403
32. Zhang W., Vallbohmer D., Yun J., et al. Pharmacogenomic study of EGFR-positive metastatic colorectal cancer patients treated with epidermal growth factor receptor (EGFR) inhibitor cetuximab (C225). Proc Gastrointest Am Soc Clin Oncol Symp 168 (2005) A169
33. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
34. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
35. Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101 (2004) 13306-13311
36. Lenz H., Mayer R.J., Mittsching B., et al. Consistent response to treatment with cetuximab monotherapy in patients with metastasic colorectal cancer. Proc Am Soc Clin Oncol 23 (2005) 255s (A3536)
37. Motwani M., Rizzo C., Sirotnak F., et al. Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells. Mol Cancer Ther 2 (2003) 549-555
38. Thomas J.P., Tutsch K.D., Cleary J.F., et al. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol 50 (2002) 465-472
39. Schwartz G.K., Ilson D., Saltz L., et al. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 19 (2001) 1985-1992
40. Shah M.A., Kortmansky J., Gonen M., et al. Phase I study of weekly irinotecan (CPT), cisplatin (CIS) and flavopiridol (F). Proc Am Soc Clin Oncol 23 (2004) 319 (A4027)
41. Schwartz G.K., O'Reilly E., Ilson D., et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol 20 (2002) 2157-2170
42. Rathkopf D.E., Ilson D.H., Yi S., et al. A phase II trial of sequential paclitaxel and flavopiridol in patients with metastatic paclitaxel-refractory esophageal cancer. Proc Gastrointest Am Soc Clin Oncol (2004) 116a (A67)
43. Fornier M.N., Rathkopf D., Shah M., et al. Phase I dose-finding study of weekly (W) docetaxel (T) followed by flavopiridol (F) for patients with metastatic solid tumors. Ann Oncol 15 Suppl. 3 (2004) iii103 (A386PD)
44. Kordes U., Krappmann D., Heissmeyer V., et al. Transcription factor NF-κB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia 14 (2000) 399-402
45. Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet 355 (2000) 248-250
46. Kahl B.S. Update: gastric MALT lymphoma. Curr Opin Oncol 15 (2003) 347-352
47. Brown K., Park S., Kanno T., et al. Mutual regulation of the transcriptional activator NF-κB and its inhibitor, IκB-α. Proc Natl Acad Sci USA 90 (1993) 2532-2536
48. Patel N.M., Nozaki S., Shortle N.H., et al. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide. Oncogene 19 (2000) 4159-4169
49. Shah M.A., Holen K., Singh D., et al. A multicenter, two-stage, phase II study of PS-341 in patients with unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. Proc Gastrointest Am Soc Clin Oncol 103 (2005) A41
50. Ocean A.J., Schnoll-Sussman F., Chen X., et al. Phase II study of PS-341 (bortezomib) with or without irinotecan in patients (pts) with advanced gastric adenocarcinomas (AGA). Proc Gastrointest Am Soc Clin Oncol 98 (2005) A31
51. Ocean A.J., Lane M.E., Xiang Z., et al. Genetic análisis of proteasome-related pathways in advanced gastric adenocarcinomas (AGA) treated on a phase II study with the proteasome inhibitor, PS-341 (bortezomib) with or without irinotecan. Proc Gastrointest Am Soc Clin Oncol 117 (2005) A69
52. Chambers A.F., and Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89 (1997) 1260-1270
53. Nomura H., Sato H., Seiki M., et al. Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res 55 (1995) 3263-3266
54. Honda M., Mori M., Ueo H., et al. Matrix metalloproteinase-7 expression in gastric cancer. Gut 39 (1996) 444-448
55. Sier C.F., Kubben F.J., Ganesh S., et al. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 74 (1996) 413-417
56. Monig S.P., Baldus S.E., Hennecken J.K., et al. Expression of MMP-2 is associated with progression and lymph node metastasis of gastric carcinoma. Histopathology 39 (2001) 597-602
57. Kimata M., Otani Y., Kubota T., et al. Matrix metalloproteinase inhibitor, marimastat, decreases peritoneal spread of gastric carcinoma in nude mice. Jpn J Cancer Res 93 (2002) 834-841
58. Watson S.A., Morris T.M., Collins H.M., et al. Inhibition of tumor growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA. Br J Cancer 81 (1999) 19-23
59. Tierney G.M., Griffin N.R., Stuart R.C., et al. A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer. Eur J Cancer 35 (1999) 563-568
60. Bramhall S.R., Hallissey M.T., Whiting J., et al. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer 86 (2002) 1864-1870
61. Carmeliet P. Angiogenesis in health and disease. Nat Med 9 (2003) 653-660
62. Ferrara N., and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 18 (1997) 4-25
63. Akagi M., Kawaguchi M., Liu W., et al. Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer. Br J Cancer 88 (2003) 782-796
64. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., et al. Phase II, randomized trial comparing Bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21 (2003) 60-65
65. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
66. Kabbinavar F., Schulz J., McCleod M., et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastasic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23 (2005) 3697-3705
67. Giantonio B.J., Catalano P.J., Meropol N.J., et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer. Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc Am Soc Clin Oncol 24 (2005) 1s (A2)
68. Shah M.A., Ilson D., Ramanathan R.K., et al. A multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. Proc Am Soc Clin Oncol 24 (2005) 314s (A4025)
69. Tokuyama J., Kubota T., Saikawa Y., et al. Tyrosine kinase inhibitor SU6668 inhibits peritoneal dissemination of gastric cancer via supresion of tumor angiogenesis. Anticancer Res 25 (2005) 17-22
70. McCarty M.F., Wey J., Stoeltzing O., et al. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. Mol Cancer Ther 3 (2004) 1041-1048
71. Jung Y.D., Mansfield P.F., Akagi M., et al. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer 38 (2002) 1133-1140
72. Ciardiello F., Bianco R., Damiano V., et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 6 (2000) 3739-3747
73. Saltz L.B., Lenz H.J., Hochster H., et al. Randomized phase II trial of cetuximab/bevacizumab/irinotecan versus cetuximab/bevacizumab in irinotecan-refractory colorectal cancer. Proc Am Soc Clin Oncol 24 (2005) 248s (A3508)
74. Fenoglio-Preiser C.M., Wang J., Stemmermann G.N., et al. TP53 and gastric carcinoma: a review. Hum Mutat 21 (2003) 258-270
75. Tolbert D., Fenoglio-Preiser C., Noffsinger A., et al. The relation of p53 gene mutations to gastric cancer subsite and phenotype. Cancer Causes Control 10 (1999) 227-231
76. Jackson J.R., Gilmartin A., Imburgia C., et al. An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage. Cancer Res 60 (2000) 566-572
77. Graves P.R., Yu L., Schwarz J.K., et al. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 275 (2000) 5600-5605